Shilpa Medicare announces positive Phase 3 results for Oeris
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Dragon Copilot integrates generative AI, ambient listening, and natural language processing (NLP) to capture and document care directly
The partnership aligns with the launch of Oracle Health’s next-generation electronic health record
Sumatriptan injection is indicated in adults for the acute treatment of migraine
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
The device delivers clear, high-quality images to support accurate diagnoses across a broad range of patient groups
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
Subscribe To Our Newsletter & Stay Updated